Ibrutinib expanded to newly diagnosed CLL patients
Ibrutinib just became the latest therapy for blood cancers to receive an expanded approval use by the U.S. Food and Drug Administration. Such therapeutic advances have been making great progress in recent months and a number of investigational agents – first approved for one disease and population – are being expanded to new uses.
Almost 300 drugs for blood cancers are currently in clinical trials or awaiting FDA review.
It’s time for the 5th annual Light The Night t-shirt design contest, and all designers – amateur or professional – are encouraged to submit their best work.
Here are the details.
What...
The Light The Night Walk is a fundraising campaign benefiting The Leukemia & Lymphoma Society (LLS) and the funding of research to find blood cancer cures. Participants across the nation join together for inspirational and memorable evening walks, carrying illuminated lanterns to take steps to end cancer. Since the walks began in 1999, this national program has helped LLS invest more than $1 billion in research to advance breakthrough treatments that are saving lives today.
This year’s Light The Night Executive Challenge ended with a bittersweet roundup of results. The winner, Stacey Weathers, former long-time executive director of The Leukemia & Lymphoma Society’s (LLS) New Jersey chapter, was tragically killed this past October when a tree fell on her car during a storm. Even though she isn’t here to celebrate with her LLS colleagues and family, her worthy achievement will be recognized as her legacy lives on.
A Powerful Force
The Light The Night Executive Challenge is a national fundraising competition for corporate executives across the nation to personally raise funds for LLS. Executives take part in raising funds by collecting donations to help support LLS to find cures for blood cancers.
Challengers who individually raise $5,000 or more are included in the “Executive Challenge Class of 2015” and have an LLS research grant named in their honor.
Here are the details.